RISS 검색 - 국내학술지논문

무료
기관 내 무료
유료

내보내기
내책장담기
한글로보기

정확도순

내림차순

내림차순

10개씩 출력

1
Plasma Brain-Derived Neurotrophic Factor as a Candidate Bio-Marker of the Neuroplastic Changes Related with Fluoxetine Administration in Major Depressive Disorder

TaeYoung Hwang,ShinnWon Lim,Jihea Yun,DohKwan Kim 대한신경정신의학회 2006 PSYCHIATRY INVESTIGATION Vol.3 No.2
- 원문보기 2
  ScienceON
  
  스콜라
Objective: The aim of this study was to investigate whether plasma brain-derived neurotrophic factor (BDNF) could be a biological marker related to the pathophysiology of depression and the action mechanism of antidepressants in patients with major depressive disorder (MDD). Methods and Materials: Forty-nine patients with MDD and 34 normal controls were recruited and analyzed for this study. The severity of depression was measured using the 17-item Hamilton Rating Scale for Depression (HAM-D-17) for MDD patients before and after a 6-week treatment with the antidepressant, fluoxetine. A minimum baseline HAM-D-17 score of 15 was required for study inclusion. The plasma BDNF was measured in all subjects at baseline and after the 6-week treatment (for the patients). Treatment outcome was measured as response ( ≥50% improvement on HAM-D-17) and remission (final HAM-D-17 score≤ 7). Results: There were no significant differences in age and gender distribution, or in baseline plasma BDNF, between the MDD and control groups. The severity of depression and plasma BDNF level at baseline were not significantly correlated. There was no significant change in the plasma BDNF of the MDD group after the 6-week treatment, although a modest trend to decrease was noted (Wilcoxon’s signed rank test, S= -186.5, p=0.0629). In addition, there was no significant difference in the change of plasma BDNF between responders and non-responders. Conclusions: The findings of this study do not support the proposed hypothesis that plasma BDNF plays a significant role as a biological marker in reflecting the neuroplastic change related to the short-term effect of antidepressants in MDD. Nevertheless, the possibility of false negative findings suggests that further studies are necessary to replicate the findings.
2
Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response

ByongSu Jang,Hyeran Kim,ShinnWon Lim,KiWon Jang,DohKwan Kim 대한신경정신의학회 2008 PSYCHIATRY INVESTIGATION Vol.5 No.3
- 원문보기 3
  ScienceON
  
  KCI
  
  스콜라
Objective-S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive patients to those of normal controls. In addition, we compared the serum S100B levels of antidepressant responders to those of nonresponders. Methods-Thirty five normal controls and 59 depressive patients were enrolled in this study. Depressive patients entered a 6 week clinical trial that included treatment with antidepressants. The serum S100B levels and clinical assessments, which included Hamilton depression rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and nonresponders was then compared. Results-There were no significant differences in the serum S100B levels of normal controls and depressive patients. In addition, 30 of the depressive patients responded to antidepressant treatment while 29 did not. Finally, the responders had significantly higher baseline serum S100B levels than the nonresponders. Conclusion-The results of this study suggest that the baseline serum S100B level is associated with the subsequent response to antidepressants. In addition, the high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants.
3
Extrapyramidal Signs and Risk of Progression from Mild Cognitive Impairment to Dementia: A Clinical Research Center for Dementia of South Korea Study

Woojae Myung,JinHong Park,SookYoung Woo,Seonwoo Kim,SangHa Kim,JaeWon Chung,HyoShin Kang,ShinnWon Lim,Junbae Choi,Duk L. Na,SeongYoon Kim,JaeHong Lee,SeolHeui Han,SeongHye Choi,SangYun Kim,Bernard J. 대한신경정신의학회 2017 PSYCHIATRY INVESTIGATION Vol.14 No.6
- 원문보기 3
  ScienceON
  
  KCI
  
  스콜라
Objective-Extrapyramidal signs (EPS) are common in patients with mild cognitive impairment (MCI). However, few studies have assessed the effect of EPS on the clinical course of MCI. We aimed to evaluate whether patients with EPS show more frequent progression from MCI to Alzheimer’s disease (AD) and to other types of dementia. Methods-Participants (n=882) with MCI were recruited, and were followed for up to 5 years. The EPS positive group was defined by the presence of at least one EPS based on a focused neurologic examination at baseline. Results-A total of 234 converted to dementia during the follow-up period. The risk of progression to AD was lower in the patients with EPS after adjusting for potential confounders [hazard ratio (HR)=0.70, 95% confidence interval (CI)=0.53-0.93, p=0.01]. In contrast, the patients with EPS had a six-fold elevated risk of progression to dementia other than AD (HR=6.33, 95%CI=2.30–17.39, p<0.001). Conclusion-EPS in patients with MCI is a strong risk factor for progression of MCI to non-Alzheimer dementia. The careful neurologic examination for EPS in patients with MCI can yield important clinical information for prognosis.